April 2, 2012

DaVinci Biosciences & Cellteam Biotechnology Combine Their Knowledge in the Stem Cell Field

(Costa Mesa, CA) April 2, 2012 – Cellteam Biotechnology, a company based in Guadalajara, Mexico and DaVinci Biosciences LLC, a biotechnology laboratory based in Costa Mesa, California, USA, today announced their Cooperation Agreement to combine the expertise and technology that will be shared between the companies in the field of clinical application of stem cell therapies.
 The two-year agreement will allow Cellteam Biotechnology to combine their technology with the Good Laboratory Practices (GLP) and technical knowledge developed in DaVinci Biosciences’ research laboratory; where research-grade biological tools are developed to progress future therapeutic applications. DaVinci Biosciences has several publications that support the seriousness of its research, and the feasibility of clinical applications using stem cells and cell-based tools. Additionally, Cellteam Biotechnology has COFEPRIS approved protocols for autologous stem cell application (cells used by a patient after being obtained from the patient’s own bone marrow) and will provide clinical feedback to DaVinci Biosciences during treatments.

About Cellteam Biotechnology
The medical team that comprises Cellteam Biotechnology has over seven years experience in the treatment of heart disease, cardiovascular disease, heart failure, ischemic heart disease, stroke, vasculitis and limb ischemia with vascular problems. Also, treatments using platelet rich plasma (PRP) for trauma have been successful. By cooperating with DaVinci Biosciences, Cellteam Biotechnology is looking to expand their knowledge in the stem cell field, in order to develop treatment protocols for investigative therapies for sports injury, diabetes, smoking-related pulmonary damage, chronic obstructive pulmonary disease, neurological diseases, spinal cord injury, immunological disease, arthritis, osteoarthritis, and ulcers. These, along with other diseases, are giving way to the body's natural power to mitigate degeneration.

About DaVinci Biosciences
DaVinci Biosciences is a private biotechnology company dedicated to generating technological breakthroughs in the stem cell field and to improving the quality of life for those suffering from injuries or degenerative disease. Through responsible research in conjunction with universities, medical research institutions and hospitals worldwide, DaVinci Biosciences is focused on being a leader in regenerative medicine and biotechnology, developing advancements for unmet medical needs. DaVinci Biosciences’ studies have been recognized in many publications and document results obtained in the quest to improve quality of life for those suffering from disease and injury. This alliance of hope between two countries and two professional companies, seek to provide hope to patients and relatives of those suffering from degenerative disease and injury.

March 6, 2012

Santo Domingo - Dominican Republic. Autologous Stem Cells Conference.

After the success and subsequent additional interest generated as a result of DaVinci Biosciences’ participation in the November 2011 “Current and Future Use of Stem Cells in the Treatment of Neurological and Cardiac Disease and Sports Injury” presentation led in part by Dr. Rafael Gonzalez, Vice President of Research and Development for DaVinci Biosciences, USA; DaVinci Biosciences was again asked to return by special invitation to speak at the conference entitled “Advances in the Use of Stem Cells in Autoimmune and Degenerative Diseases” held in one of the most prestigious hotels in the Dominican capital. The event was hosted by BRC Center and Dr. Alejandro Dominguez Brito and is the second in a planned series of discussions to take place in Santo Domingo, aimed at educating the community on the current state and future therapeutic applications of stem cells.

Both physicians and patients attended the conference as Dr. Rafael Gonzalez was joined by leaders in the stem cell and regenerative medicine field, including Dr. Jesus Esparragoza Romano, Interventional Cardiologist and Medical Director for Cellteam Biotechnology in Guadalajara, Mexico, and Dr. Maria del Pilar Santacruz, Medical Director for CellGen Technologies in Ecuador. The conference focused on the ethical and successful application of autologous stem cell therapies which result from the use of a patient’s own stem cells for therapeutic effect and improvement of quality of life for those suffering from disease and injury. Discussions focused on the quantifiable scientific effects of such procedures and specifically on statistical data including those published in peer reviewed journals supporting the efficacy of such treatments. Video testimony shared from patients that had undergone such therapies gave hope to hundreds of audience members that this is truly a revolutionary approach to treating disease.

Dr. Dominguez Brito, a respected physician in the Dominican Republic, is responsible for evaluating patients who may be good candidates for autologous stem cell therapies. Dr. Dominguez Brito works closely with hospitals and treatment centers to make sure qualified candidates receive optimal and individualized treatment tailored to their specific need, be it for autoimmune, vascular, cardiac, pulmonary, neurological or orthopedic diseases; providing hope for individual families as well as to the field of regenerative medicine on a global level.

December 14, 2011

Guayaquil – Ecuador. Discussion on Advances in Autologous Stem Cell Therapies.

DaVinci Biosciences was invited to participate in a discussion entitled “Advances in Investigational Autologous Stem Cell Therapies” held at Omni Hospital in Guayaquil, Ecuador. Dr. Rafael Gonzalez, PhD, Vice President of Research and Development for DaVinci Biosciences, USA joined Dr. Maria del Pilar Santa Cruz, Medical Director for Cellgen Technologies, Ecuador and Dr. Manuel Navarro, Endocrinologist for Cellgen Technologies, Ecuador, to discuss advances in stem cell research and clinical applications for cardiovascular, endocrine and neurodegenerative diseases.

The discussion generated great interest among leading physicians of various specialties within Ecuador. In attendance also was Dr. Gonzalo W. Maitta Mendoza, Dean of the Medical Faculty of Universidad de Guayaquil, Ecuador, Dr. Luis Sarrazin, former Minister of Public Health, Ecuador, and Biologists Alexandra Narvaez and Edith Lopez of Universidad Espiritu Santo, Ecuador, all prominent key opinion leaders in the field of stem cell therapy and research.

November 2011

Santo Domingo - Dominican Republic. The Future of Stem Cells Presentation.

A lecture entitled "Current and Future Use of Stem Cells in the Treatment of Neurological and Cardiac Disease and Sports Injury” by Dr. Rafael Gonzalez, Vice President of Research and Development for DaVinci Biosciences, USA, along with Dr. Maria del Pilar Santacruz, Medical Director for CellGen Technologies at Omni Hospital, Ecuador was given in the presence of leading regenerative medicine professionals in the Domincan Republic. The meeting was organized by DaVinci Biosciences and focused on the clinical applications of stem cells for degenerative disorders for which the company is in active development. Dr. Gonzalez is responsible for the design and implementation of DaVinci’s pre-clinical and clinical therapeutic adult stem cell development which includes stem cells isolated from bone marrow, menstrual blood, and fat. Dr. Santacruz’s efforts have helped progress the initial therapeutic treatment approvals by governmental agencies to successful autologous stem cell transplants, leading to treatment of degenerative and autoimmune diseases in Ecuador’s finest clinical facility.

April 2010

In a paper published in the scientific journal Cell Transplantation, volume 19, 1439-1449, 2010, DaVinci Biosciences describes “An Efficient Approach to Isolation and Characterization of Pre- and Postnatal Umbilical Cord Lining Stem Cells for Clinical Applications”.

February 24th - 27th, 2010

DaVinci Biosciences will be speaking at XII Congreso Internacional Avances en Medicina 2010, Hospital Civil de Guadalajara

The conference will be held in Expo Guadalajara, from February 24th to 27th, 2010.

January 2010

DaVinci Biosciences signs technology licensing agreement with Cryobanks India to enable the production of Umbilical Cord Lining Stem Cells. For more information contact us directly.

January 30, 2010

Dr Rafael Gonzalez, Director of Research & Development invited to present DaVinci Biosciences’ work on mesenchymal stem cells at the National Science Forum in Guayaquil, Ecuador. The presentation entitled, ”Isolation of Mesenchymal Stem Cells from Various Adult Sources”, covers various forms of mesenchymal stem cell characterization and studies by DaVinci Biosciences.

Cell Transplantation (Issue Vol.19 No.3)

In a paper published in the Vol.19 No.3 issue of Cell Transplantation, DaVinci Biosciences publishes a safety and feasibility trial for treating patients suffering from acute and chronic spinal cord injury using stem cells.

Read the abstract for "Administration of Autologous Bone Marrow Stem Cells Into Spinal Cord Injury Patients Via Multiple Routes Is Safe and Improves Their Quality of Life: Comprehensive Case Studies" published in Cell Transplantation.

SFN 2009 Presentation

Administration of Adult Bone Marrow Stem Cells into Spinal Cord Injury Patients via Multiple Routes is Safe and Feasible.

October 21, 2009

DaVinci Biosciences’ presentation at Society for Neuroscience Annual Meeting earns label of “Hot Topic”.

October 19, 2009

Presentation of adult stem cell study highlights promising application of autologous stem cells for treatment of spinal cord injury.

June 8, 2009

Orthopedics This Week highlights article published by DaVinci Biosciences.

June 4, 2009

In a paper published in the scientific journal of Biochemical and Biophysical Research Communications, volume 385, 2009 DaVinci Biosciences describes a novel source of stem cells easily isolated from adult human testes.

June 4, 2009

International stem cell collaboration results in discovery of promising new stem cell type.

March 12, 2009

Stem cell administration study demonstrates improved quality of life for patients suffering from spinal cord injury.